she had no issues around the 3rd dose; she had no issues around the 3rd dose; increased joint pain (unspecified); loss of flexibility; This is a spontaneous report from a contactable other hcp.  A 61-year-old female patient received third dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection; Lot Number: Unknown), via an unspecified route of administration as on unspecified date in Sep2021 as dose 3 (booster), single for covid-19 immunisation. Medical history included unable to get up or get out of bed, joint plus ligaments were painful, ligament pain and had little swollen places on the bottoms of her feet all from an unknown date and unknown if ongoing. Concomitant medications included tofacitinib citrate (XELJANZ) as 11 mg oral daily per oral from 2020 and ongoing for Rheumatoid Arthritis. Historical vaccine included patient previously took first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection; Lot Number: Unknown), via an unspecified route of administration on unspecified date in 2021 as dose 1, single and took second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection; Lot Number: Unknown), via an unspecified route of administration on unspecified date in Feb2021 as dose 2, single both for covid-19 immunisation and experienced the first time she had a "little flare up" that took her a couple of months to return to normal from after second dose.On unspecified date in Sept2021, she had no issues around the 3rd dose. on unspecified date in 2021, Patient experienced increased joint pain (unspecified) and loss of flexibility due to the missed doses which for the most part has subsided since resuming therapy (date unknown) but some of it still lingering due to the cold weather. Patient reported to holding therapy per MD for 7 days after the 2nd covid vaccine (about 8 months ago) and booster (1 month ago). Patient reported that xeljanz was working. Patient stated that prior to taking xeljanz she was unable to get up or get out of bed, every joint plus ligaments were painful, and she had little swollen places on the bottoms of her feet. patient reported that she still had some pain, but she can function at 85 percent of her normal. Patient reported stopped xeljanz for 1 week around each of the 2nd and 3rd doses of covid vaccine. patient stated that the first time she had a little flare up that took her a couple of months to return to normal from. Stated that she had no issues around the 3rd dose when she stopped xeljanz therapy for a week. No further details given. unknown if md aware. Therapeutic measure were taken for event loss of flexibility, increased joint pain (unspecified). The outcome of the events was unknown.  Follow-up (28Oct2021): This is a follow up-spontaneous report from a contactable other HCP. This other HCP reported for the patient in response to HCP letter [sent to physician] via follow-up letter which included that: Concomitant medication (start date and route of administration) added new event increased joint pain (unspecified) and loss of flexibility and narrative was updated with clinical information. This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts completed. No further information is expected.